Therapeutic drug monitoring of cyclosporine and tacrolimus

Clinical Biochemistry

Volumn 31, Issue 5, 1998, Pages 309-316

  Oellerich, Michael ^a   Armstrong, Victor W ^a   Schütz, Ekkehard ^a   Shaw, Leslie M ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN; CYCLOSPORIN A; FK 506 BINDING PROTEIN; IMMUNOPHILIN; TACROLIMUS;

AREA UNDER THE CURVE; CLINICAL PROTOCOL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOSUPPRESSIVE TREATMENT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICROPARTICLE ENZYME IMMUNOASSAY; ORGAN TRANSPLANTATION; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ADULT; CHILD; CYCLOSPORINE; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; SENSITIVITY AND SPECIFICITY; TACROLIMUS;

EID: 0032128129     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(98)00049-6     Document Type: Conference Paper

References (22)

1. Jusko W.J., Thomson A.W., Fung J., et al. Consensus document therapeutic monitoring of tacrolimus (FK-506) . Ther Drug Monit. 17:1995;606-614.
2. Oellerich M., Armstrong V.W., Kahan B., et al. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation report of the consensus panel . Ther Drug Monit. 17:1995;642-654.
3. Halloran P.F. Molecular mechanisms of new immunosuppressants. Clin Transplant. 10:1996;118-123.
4. Taylor P.J., Jones A., Balderson G.A., et al. Sensitive, specific quantitative analysis of tacrolimus (FK 506) in blood by liquid chromatography-electrospray tandem mass spectrometry. Clin Chem. 42:1996;279-285.
5. Zhang Q., Simpson J., Aboleneen H.I. A specific method for the measurement of tacrolimus on human whole blood by liquid chromatography/tandem mass spectrometry. Ther Drug Monit. 19:1997;470-476.
6. Gonschior A.K., Christians U., Winkler M., et al. Tacrolimus (FK 506) metabolite patterns in blood from liver and kidney transplant patients. Clin Chem. 42:1996;1426-1432.
7. Winkler M., Christians U., Baumann J., et al. Evaluation of the Pro-Tac tacrolimus monoclonal whole-blood enzyme-linked immunosorbent assay for monitoring of tacrolimus levels in patients after kidney, heart and liver transplantation. Ther Drug Monit. 18:1996;640-646.
8. Braun F., Lorf T., Schütz E., et al. Clinical relevance of monitoring tacrolimus comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus . Transplant Proc. 28:1996;3175-3176.
9. Tamura K., Fujimura T., Iwasaki K., et al. Interaction of tacrolimus (FK 506) and its metabolites with FKBP and calcineurin. Biochem Biophys Res Commun. 202:1994;437-443.
10. Soldin S.J. Receptor (immunophilin-binding) assay for immunosuppressive drugs. Ther Drug Monit. 17:1995;574-576.
11. Armstrong V.W., Schütz E., Groothiusen S., et al. Pentamer formation assay for determination of tacrolimus and its active metabolites in whole blood. Ther Drug Monit. 19:1997;554.
12. Braun F., Schütz E., Christians U., et al. Pitfalls in monitoring tacrolimus (FK506). Ther Drug Monit. 19:1997;628-631.
13. Sher L.S., Cosenza C.A., Michel J., et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation. Transplantation. 64:1997;258-263.
14. Ringe B, Braun F, Lorf T, et al. FK and MMF in clinical liver transplantation: experience with a steroid sparing concept. Transpl Proc 1998; in press.
15. Huupponen R., Hirvisalo E.L., Neuvonen P. Comparison of cyclophilin binding assay and radioimmunoassay in monitoring of blood cyclosporine. Ther Drug Monit. 19:1997;446-449.
16. Batiuk T.D., Pazderka F., Hollaran P.F. Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients. Transplantation. 59:1995;1400-1404.
17. Keown P., Landsberg D., Halloran P., et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation. 62:1996;1744-1752.
18. Laine J., Hoppu K., Jalanko H., et al. Kidney function after 1:1 conversion to the cyclosporine microemulsion formulation in children with liver allografts. Transplantation. 63:1997;1768-1772.
19. Kahan B.D., Dunn J., Fitts C., et al. The neoral formulation improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients . Transplant Proc. 26:1994;2940-2943.
20. Mueller E.A., Kovarik J.M., Van Bree J.B., et al. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients - a concentration-controlled comparison with the commercial formulation. Transplantation. 57:1994;1178-1182.
21. Freeman D., Grant D., Levy G., et al. Pharmacokinetics of a new oral formulation of cyclosporine in liver transplant recipients. Ther Drug Monit. 17:1995;213-216.
22. Amante A.J., Kahan B.D. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period. Transplant Proc. 28:1996;2162-2163.